The solution features clinically proven digital diagnostics and therapy, delivering up to 20% immediate PPD symptom relief and 30-40% improvement…
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in…
OvaStem® Demonstrates Strong Long-Term Efficacy with No Safety Concerns, Backed by Pending Orphan Drug Designation for AlloStem®PHOENIX, Feb. 20, 2025…
ATLANTA, Feb. 19, 2025 /PRNewswire/ -- SteelSky Ventures, the world's leading women's health fund, has made a strategic investment in…
BOCA RATON, Fla., Feb. 13, 2025 /PRNewswire/ -- Arkstone, the leader in laboratory infectious disease guidance and antimicrobial stewardship, proudly…
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal…
First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food…
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics…
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension Saqib Islam, SpringWorks Therapeutics…
UK regulatory approval follows FemaSeed, FemVue and FemCerv clearance/ approvals in the U.S., Europe, Canada and IsraelATLANTA, Feb. 11, 2025…